BridgeBio Pharma, Inc.
BBIOPharmaceutical Preparations · SIC 2834 · CIK 0001743881
Revenue FY2025
$0.50B
Net Income
$(0.73B)
EPS (Basic)
$-3.78
Net Margin
-146.0%
ROE
35.1%
Total Equity
$(2.09B)
Shares Out
195M
BridgeBio Pharma, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 10 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Viking Global Investors
Andreas Halvorsen
$741.0M
0.9%
(16.0%)
Platinum Investment Management
Platinum Investment Management
$3.0M
0.7%
(19.3%)
Adage Capital Management
Adage Capital Management
$167.7M
0.2%
+276.0%
Royce & Associates
Royce & Associates
$16.3M
0.1%
(6.2%)
Renaissance Technologies
Renaissance Technologies
$63.8M
0.1%
+134.3%
Bridgewater Associates
Bridgewater Associates
$33.4M
0.0%
+72.7%
WCM Investment Management
WCM Investment Management
$11.9M
0.0%
(1.7%)
Motley Fool Asset Management
Motley Fool Asset Management
$0.3M
0.0%
(0.6%)
Capital Research Global Investors
Capital Research Global Investors
$52.1M
0.0%
(8.3%)
Polen Capital Management
Polen
$0.3M
0.0%
(91.3%)
Insider Transactions
Reading stored insider transactions…